(ASTH) Astrana Health - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.877m USD | Total Return: 54.4% in 12m
Avg Turnover: 16.3M
EPS Trend: 90.1%
Qual. Beats: 0
Rev. Trend: 98.6%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Supp Ema8, Supp Ema20, Rs Leader, Idiosyncratic Leader, Confidence
Astrana Health, Inc., formerly Apollo Medical Holdings, Inc., is a California-based healthcare management firm operating through three integrated segments: Care Partners, Care Delivery, and Care Enablement. The company facilitates coordinated medical services across a network of primary care physicians, specialists, and acute care facilities, primarily serving patients under Medicare, Medicaid, and private insurance plans.
The company operates within the value-based care sector, a model that incentivizes healthcare providers based on patient health outcomes rather than the volume of services performed. This approach typically involves taking on financial risk for patient populations, requiring sophisticated data analytics to manage costs and clinical quality effectively.
For a deeper look into the companys valuation metrics and historical performance, ValueRay provides comprehensive data tools. Astrana Health continues to expand its physician network and care coordination infrastructure to capture growth in the shifting U.S. healthcare reimbursement landscape.
- Expansion into new geographic markets drives membership growth and total revenue
- Value-based care model profitability depends on managing medical loss ratios effectively
- Strategic acquisitions of physician groups accelerate network scale and market share
- Medicare Advantage reimbursement rate changes impact core segment operating margins
- Regulatory shifts in Medicaid funding influence long-term care delivery profitability
| Net Income: 30.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.66 > 1.0 |
| NWC/Revenue: 7.34% < 20% (prev 11.20%; Δ -3.86% < -1%) |
| CFO/TA 0.07 > 3% & CFO 166.0m > Net Income 30.2m |
| Net Debt (624.4m) to EBITDA (148.9m): 4.19 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.1m) vs 12m ago 0.42% < -2% |
| Gross Margin: 9.31% > 18% (prev 0.12%; Δ 919.3% > 0.5%) |
| Asset Turnover: 191.1% > 50% (prev 169.1%; Δ 22.08% > 0%) |
| Interest Coverage Ratio: 1.61 > 6 (EBITDA TTM 148.9m / Interest Expense TTM 58.7m) |
| A: 0.11 (Total Current Assets 1.00b - Total Current Liabilities 745.4m) / Total Assets 2.36b |
| B: 0.14 (Retained Earnings 322.7m / Total Assets 2.36b) |
| C: 0.05 (EBIT TTM 94.5m / Avg Total Assets 1.85b) |
| D: 0.18 (Book Value of Equity 322.8m / Total Liabilities 1.78b) |
| Altman-Z'' = 1.70 = BBB |
| DSRI: 0.97 (Receivables 500.1m/328.6m, Revenue 3.53b/2.25b) |
| GMI: 1.31 (GM 9.31% / 12.17%) |
| AQI: 1.06 (AQ_t 0.53 / AQ_t-1 0.50) |
| SGI: 1.57 (Revenue 3.53b / 2.25b) |
| TATA: -0.06 (NI 30.2m - CFO 166.0m) / TA 2.36b) |
| Beneish M = -2.39 (Cap -4..+1) = BBB |
As of May 27, 2026, the stock is trading at USD 38.54 with a total of 431,688 shares traded.
Over the past week, the price has changed by -1.13%,
over one month by +13.32%,
over three months by +84.31% and
over the past year by +54.35%.
Astrana Health has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy ASTH.
- StrongBuy: 9
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.6 | 15.6% |
P/E Trailing = 62.0492
P/E Forward = 23.0415
P/S = 0.5322
P/B = 2.3433
Revenue TTM = 3.53b USD
EBIT TTM = 94.5m USD
EBITDA TTM = 148.9m USD
Long Term Debt = 979.8m USD (from longTermDebt, last quarter)
Short Term Debt = 55.4m USD (from shortTermDebt, last quarter)
Debt = 1.10b USD (from shortLongTermDebtTotal, last quarter) + Leases 37.6m
Net Debt = 624.4m USD (calculated: Debt 1.10b - CCE 478.4m)
Enterprise Value = 2.50b USD (1.88b + Debt 1.10b - CCE 478.4m)
Interest Coverage Ratio = 1.61 (Ebit TTM 94.5m / Interest Expense TTM 58.7m)
EV/FCF = 16.14x (Enterprise Value 2.50b / FCF TTM 155.0m)
FCF Yield = 6.20% (FCF TTM 155.0m / Enterprise Value 2.50b)
FCF Margin = 4.40% (FCF TTM 155.0m / Revenue TTM 3.53b)
Net Margin = 0.86% (Net Income TTM 30.2m / Revenue TTM 3.53b)
Gross Margin = 9.31% ((Revenue TTM 3.53b - Cost of Revenue TTM 3.20b) / Revenue TTM)
Gross Margin QoQ = 9.35% (prev 8.27%)
Tobins Q-Ratio = 1.06 (Enterprise Value 2.50b / Total Assets 2.36b)
Interest Expense / Debt = 5.32% (Interest Expense 58.7m / Debt 1.10b)
Taxrate = 33.38% (6.58m / 19.7m)
NOPAT = 63.0m (EBIT 94.5m * (1 - 33.38%))
Current Ratio = 1.35 (Total Current Assets 1.00b / Total Current Liabilities 745.4m)
Debt / Equity = 1.38 (Debt 1.10b / totalStockholderEquity, last quarter 800.3m)
Debt / EBITDA = 4.19 (Net Debt 624.4m / EBITDA 148.9m)
Debt / FCF = 4.03 (Net Debt 624.4m / FCF TTM 155.0m)
Total Stockholder Equity = 780.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.64% (Net Income 30.2m / Total Assets 2.36b)
RoE = 3.88% (Net Income TTM 30.2m / Total Stockholder Equity 780.1m)
RoCE = 5.37% (EBIT 94.5m / Capital Employed (Equity 780.1m + L.T.Debt 979.8m))
RoIC = 3.95% (NOPAT 63.0m / Invested Capital 1.60b)
WACC = 6.71% (E(1.88b)/V(2.98b) * Re(8.57%) + D(1.10b)/V(2.98b) * Rd(5.32%) * (1-Tc(0.33)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 76.41 | Cagr: 1.42%
[DCF] Terminal Value 77.97% ; FCFF base≈113.8m ; Y1≈130.5m ; Y5≈192.1m
[DCF] Fair Price = 45.70 (EV 2.89b - Net Debt 624.4m = Equity 2.27b / Shares 49.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.10 | EPS CAGR: 30.18% | SUE: 0.60 | # QB: 0
Revenue Correlation: 98.58 | Revenue CAGR: 47.48% | SUE: 0.80 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.73 | Chg30d=+12.31% | Revisions=+20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.79 | Chg30d=+5.33% | Revisions=+20% | Analysts=2
EPS current Year (2026-12-31): EPS=2.92 | Chg30d=+8.55% | Revisions=+20% | GrowthEPS=+37.6% | GrowthRev=+25.8%
EPS next Year (2027-12-31): EPS=3.41 | Chg30d=+14.05% | Revisions=+20% | GrowthEPS=+16.8% | GrowthRev=+9.2%
[Analyst] Revisions Ratio: +20%